Denali Therapeutics Inc.

Q3 2024 13F Holders

Symbol
DNLI
CUSIP
24823R105
Type
Equity
Class
COM
Num filings
229
Total reported value, excl. options
$3.70 B
Manager Report Date Value ($000) Shares Option Type